Regulations and Legislation by Angelovska, Bistra & Drakalska, Elena
PHARMACEUTICAL REGULATION 
AND LEGISLATION 
• The role of pharmaceuticals has become more prominent on 
international agendas as health indicators have been 
increasingly linked with a country’s successful development.  
• In addition, the legal and economic issues that surround 
pharmaceuticals have become more complex and politicized 
because of the increase in global trade.  
• the use of ineffective, poor-quality or harmful medicines can 
result in therapeutic failure, exacebration of the disease, 
resistance to medicines and sometimes death.  
• It also undermines confidence in health systems, health 
professionals, pharmaceutical manufacturers and distributors. 
To protect public health, governments need to approve 
comprehensive laws and regulations and to establish effective 
national regulatory authorities to ensure that the manufacture, 
trade and use of medicines are regulated approprietally and 
that the public has access to accurate information on 
medicines.  
Differences  
• Laws today are usually written in fairly general terms to meet 
present and possibly future needs. Laws usually have language 
that enables the government to issue regulations based on the 
law. Passing new laws may require a lengthy process with the 
country’s legislative branch giving final approval.  
• Regulations can be passed more rapidly and simply than laws, 
sometimes requiring, for example, only the approval of a 
single government minister on the advice of experts.  
• They can also be altered more easily. After approval, a 
regulation has the same power as the law itself.  
• Guidelines, which do not carry the force of law, can be more 
easily modified and updated. 
• Pharmaceuticals involve many parties, including patients, 
doctors, overhealth workers, sales representatives and 
manufacturers. The field also involves important risks: people 
can suffer and die not only from a lack of medicines, but also 
from drugs that are impure, wrongly prescribed or used 
incorrectly. Thus, it is easy to see why laws and regulations are 
needed. However, some argue that medicines-like many other 
commodities-should be subject only to the control of ultimate 
user.  
• Additionally, informal controls are insufficient: sales of 
worthless remedies- the firm action may be needed to stop it 
• However, the Internet presents new challenges in controlling 
deceitful drug promotion.  
• Counterfeiting, also, has been on the rise in developed and 
developing countries. U.S. customs officials, for example, 
report that pharmaceuticals are one of the fastest-growing 
categories of counterfeit goods coming into the country 
illegally. 
• The approach to pharmaceutical regulation should not be 
simply punitive: rules creating a positive situation tend to be 
more effective. Finally, law and regulations are effective only 
to extent that they meet society’s needs.  
GLOBALIZATION AND HARMONIZATION 
• Laws and regulations evolve within countrie over time, but in 
recent years the trend has been toward the globalization of 
pharmaceutical issues, which affect national legislation. This 
globalization, exemplified through changes in international 
trade, patent protection and pricing, has resulted in a number of 
initiatives that must be considered by countries developing 
pharmaceutical regulations: 
• 1. TRIPS Agreement. the TRIPS Agreement (Agreement on 
Trade-Related Aspects of Intellectual Property Rights) of the 
WTO has greatly affected pharmaceutical regulation. TRIPS is 
an attmpt to reduce gaps in the way intellectual property rights 
are protected around the world and to bring them under 
common international rules 
• However, the implication of the agreement’s provision on 
patients caused concerns in developing countries. In response 
to those concerns, at the Doha Conference in 2001, WTO 
members adopted a special affirmation-known as Doha 
Declaration- on issues related to TRIPS and public health.  
• The declaration affirms that the TRIPS Agreement should be 
implemented in ways that protect public health and promote 
access to medicines.  
• Driven by the increase of global trade in pharmaceutical 
products and the subsequent complexity of technical 
regulations related to medicine safety and quality, several 
initiatives have been established to promote the harmonization 
of international pharmaceutical guidelines and regulations by 
intergovernmental organizations at regional and interregional 
level 
International Conference on Drug Regulatory Authorities 
Organized by WHO, ICDRA provides officials from the drug 
regulatory authorities from all WHO member states with a forum 
to work on strengthening cooperation and collaboration. Held 
since 190, the annual conferences promote the exchange of 
information and provide a platform to develop international 
consensus on pharmaceutical regulation. The conferences are a 
unique forum that assemble all drug regulatory authorities, 
regardless of their organization stage of development. The 
ICDRA has been instrumental in guiding regulatory authorities 
on how the harmonization of regulation can improve the safety, 
efficacy and quality of medicines.  
International Conference of Harmonization 
• The International Conference of Harmonization of Technical 
Requirements for Registration of Pharmaceutical for Human 
use (ICH) is a project that brings together the regulatory 
authorities and experts from the pharmaceutical industry in 
Europe, U.S. and Japan to discuss scientific and technical 
aspects of product registration.  
• The purpose is to promote harmonization in the application of 
technical guidelines and requirements for new product 
registration in order to reduce the duplication of and to 
facilitate the evaluation of testing carried out during the 
research and development of new medicines.  
 
• Harmonization conserves resources and increases the 
availability of new medicines, while maintaining regulatory 
obligations to safeguard the products. Although intended for 
new products, ICH guidelines are also used to register existing 
products. The guidelines, formally produced by and for ICH 
member countries, reflect the technical capabilities of their 
well-developed regulatory agencies and pharmaceutical 
industries.  
• Thus, other countries should consider their local situations 
before trying to apply ICH guidelines. However, ICH 
guidelines do end up affecting all countries, particularly as 
they relate to the quality specifications of medicinal products, 
including generic medicines requirements for which vary 
considerably across coutries.  
• WHO, with its observer status on the ICH steering committee 
is expected to act as a link between ICH and non- ICH 
countries and to disseminate information to non-ICH countries. 
The ICH has also established a Global Cooperation Group that 
promotes ICH guidelines by acting as an information resourse 
for nonmembers.  
Drafting and revising pharmaceutical legislation and 
regulations 
Regulatory authorities are continually faced with new issues- 
such as globalization and extension of free trade-while increased 
responsibilities from the market expansion and the sophistication 
and new categories of products place heavy demands on 
regulatory systems.  
As a first step before drafting any new law, it is important to 
inventory the laws and regulations already in force. Even if no 
general drug law exists, pieces of legislation are likely to touch 
on the field-for example, laws on narcotics and licensing and 
responsibilities of pharmacists.  
An out-of date general drug law may exist that should be 
replaced rather than merely amended.  
• Determining the extent to which existing laws and regulations 
contribute to attaining and the national policy objectives is 
essential, because concepts of pharmaceutical policy are 
modern, legislation more than 20 years old may not be 
relevant-starting over may be simpler.  
• In countries with a long history of regulation, laws on 
pharmacists and the registration of medicines as well as 
regulation on prices and costs are likely to be separate, because 
they came into being at different times. In starting afresh, 
however, and particularly if the laws on these matters are 
outdated or incomplete, it may be easier to pull together all 
relevant elements in single law.  
• Ideally, the task of writing and revising the law should be 
entrusted to a group of legal and health experts who are 
familiar with all the issues, but not all countries can assemble 
such a group. Rather than solving the problem by copying laws 
from abroad, countries with limited expertise can obtain 
assistance from international and bilateral agencies to draft 
new pharmaceutical legislation that meets the country’s own 
needs.  
• International and regional meeting of drug regulatory 
authorities also provide opportunities for learning how to 
approach the problem and identifying expert colleagues who 
can be called on for advice.  
• At all stages of the process it s important to discuss early drafts 
of the law with all interested parties, including the health 
professions, trade and industry groups, other concerned 
government departments and consumer groups. The greater the 
consensus, the greater is the chance that a law will be passed 
and will work in practice.  
• When the law is approved, regulations are developed to guide 
the implementation of the law. Regulations can be modified 
more easily than laws as the local situation evolves. When a 
regulation is revised, it is important to research and take into 
account what other laws will be affected by the revision. 
• Declaring that a revision nullifies all previous laws and 
regulations in conflict, without makin sure what those previous 
laws cover, can result in confusion.  
 
Basic elements of pharmaceutical legislation 
A well-defined set of elements constitutes the initial 
requirements for s strong and comprehensive national 
pharmaceutical law. These elements, though basic, are 
sufficiently wide and varied in their scope to meet most of the 
objectives of a national pharmaceutical policy.: 
General provisions 
Control of availability and marketing 
Drug control administration 
Powers of enforcement 
Repeal and transitional provisions 
 
Key provisions of national pharmaceutical legislation 
Because a consumer cannot independently asses the safety, 
efficacy, or quality of pharmaceuticals, these products are 
universally recognized as being different from ordinary items of 
commerce, handling by specially trained health professionals. 
These requirements make pharmaceutical subject to numerous 
controls at all the levels.  Legal authority  is granted to regulate 
their manufacture, distribution, marketing, prescribing, labeling, 
dispensing and pricing.  
• An effective national pharmaceutical law is a primary means 
of ensuring that pharmaceutical policy goals are achieved 
while the unique character of pharmaceutical products, 
personnel and facilities is preserved. The law may specify what 
products can legally be imported-for example, those included 
on the national medicines list and processing a WHO type 
certificate of quality- and which individuals are legally 
qualified to prescribe and dispense them, thus promoting 
certain national pharmaceutical policies.  
• Likewise, control of the manufacture, storage, distribution and 
sale of pharmaceutical products enables a government to better 
ensure complience with national policy of having essential 
medicines of appropriate quality, safety and efficacy available 
for their intended purposes. 
• The processes of licensing and registration can grant 
authorization only to those personnel, products and facilities 
that conform to the national pharmaceutical law. For example, 
the counterfeit medicines or dangerous medicines can be taken 
off the market and sanctions can be taken against those 
responsible for introducing them illegally.  
• In addition, countries that host clinical trials to test new 
medicines should incorporate regulations on how the studies 
should be conducted, including an application process that 
explains the purpose and protocol of the intended research and 
the creation of an ethics committee to approve and monitor any 
study protocol that includes human participants.  
• For countries needing assistance in this area, WHO publishes 
guidelines on good clinical practices.  
• The promulgation of regulations, the collection of licensing 
and registration fees, and the enforcement of the national law 
and its regulations are legally delegated to an agency- usually 
called the national drug regulatory authority-headed by 
director who is responsible to a cabinet-level person, such as 
minister of health.  
• Regulatory authority should be vested with legal powers to: 
• - issue, vary and revoke licenses for pharmaceutical products 
on grounds of quality, safety and efficacy.  
• - ensure the safe and effective use of each product by 
controlling through the terms of the licence, the content of all 
labeling and the channels through which the product may 
legitimately be supplied. 
• - inspect and license all manufacturing premises, importing 
agents, wholesalers, distributors, independent pharmacies 
